A 2545
structure in first source
Networked: 2
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results
Related Diseases
1. | Myocardial Infarction
|
2. | Hepatocellular Carcinoma (Hepatoma)
|
3. | Cardiac Arrhythmias (Arrythmia)
12/01/1998
- " The antiarrhythmic plasma concentrations (IC50) of A-2545, 2 mg kg(-1) 10 min(-1), i.v., for 24-h and 48-h coronary ligation-, digitalis- and adrenaline-induced arrhythmias were 1.8, 1.3, 5.8 and 3.7 microg ml(-1), respectively, and that calculated for oral A-2545 (25 mg kg(-1)) in 24-h coronary ligation-induced arrhythmia was 1.8 microg ml(-1). " 12/01/1998
- " A-2545 is specifically potent in suppressing coronary ligation-induced arrhythmias, i.e., decreasing the arrhythmic ratio nearly to zero by oral administration, and among the intravenously given experiments A-2545 was effective at lower concentrations than other arrhythmia models; A-2545, 2 mg kg(-1) 10 min(-1), was equipotent to 5 mg kg(-1) 10 min(-1) mexiletine in suppressing 24-h coronary ligation-induced arrhythmia, indicating that A-2545 is more potent than mexiletine. " 12/01/1998
- " Effects of an antiarrhythmic drug A-2545 on canine ventricular arrhythmia models; comparison with mexiletine and flecainide."
|
|
Related Drugs and Biologics
Related Therapies and Procedures